Gilead Sciences, Inc. (GILD) vs Sanofi (SNY)
- Gilead Sciences, Inc. GILD 168.69 +1.30%
- Sanofi SNY 46.58 +1.13%
Gilead Sciences, Inc. and Sanofi are both Drug Manufacturers General companies. Gilead Sciences, Inc. is the larger, with a market value of $207.8B against $111.3B — 1.9× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Sanofi trades at 22.8×. Sanofi grew revenue faster over the last twelve months: 26.3% against 6.54%. Sanofi has the higher net margin (8.27% vs −12.5%) and the higher return on invested capital (7.05% vs −4.51%). Both pay a dividend; Sanofi yields more (5.25% vs 1.95%). Across the 22 metrics below, Sanofi leads on 17 and Gilead Sciences, Inc. on 5.
Valuation
Profitability
| Metric | GILD | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.93% | 73.44% | 73.01% |
| Operating margin | (7.63%) | 18.73% | 18.34% |
| Net margin | (12.47%) | 8.27% | 7.31% |
| Free cash flow margin | 44.47% | 40.26% | 18.56% |
| Return on equity | (22.45%) | 0.00% | 20.02% |
| Return on assets | (7.03%) | 3.24% | 2.28% |
| Return on invested capital | (4.51%) | 7.05% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack